Clinical Trial Update: Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update of imatinib mesylate for chronic myeloid leukemia has completed. The study included pediatric and BCR-ABL1–positive, chronic-pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Bcr-abl1 Positive

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Status: COMPLETED